FDA releases updated industry guidelines for development of generic abuse-deterrent opioid pain meds

|By:, SA News Editor

Aimed at encouraging the development of generic versions of opioid analgesics, the FDA has released a new group of 43 product-specific guidelines for industry, including three revised product-specific guidances for abuse-deterrent opioid products that recommend specific in vivo studies and in vitro study considerations for abuse-deterrent evaluations by the agency.

Selected tickers: ENDP, AGN, JNJ, TEVA, MNK, INSY, DEPO, ALKS, AMPH, COLL, EGLT, PTIE, ACUR, PTX, ACRX, IPCI, KMPH, OTCQB:ELTP, TRVN, CXW, BDSI, OPNT, MYL, PRGO

Subscribe for full text news in your inbox